PDCD4 Antikörper (AA 1-100) (Cy7)
Kurzübersicht für PDCD4 Antikörper (AA 1-100) (Cy7) (ABIN731999)
Target
Alle PDCD4 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- AA 1-100
-
Kreuzreaktivität
- Human, Maus, Ratte
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human PDCD4
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 -
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
-
Konservierungsmittel
- ProClin
-
Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
-
Haltbarkeit
- 12 months
-
-
- PDCD4 (Programmed Cell Death 4 (PDCD4))
-
Andere Bezeichnung
- Pdcd4
-
Hintergrund
-
Synonyms: H731, Programmed cell death protein 4, Neoplastic transformation inhibitor protein, Nuclear antigen H731-like, Protein 197/15a, PDCD4
Background: Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. May play a role in apoptosis. Tumor suppressor. Inhibits tumor promoter-induced neoplastic transformation. Binds RNA (By similarity).
-
Gen-ID
- 27250
-
UniProt
- Q53EL6
Target
-